Assessments
death, tumor, Cancer
ADVERSE EVENT, TUMOR, ADVERSE EVENT, CANCER
Responses were assessed by independent radiologists according to RECIST v1.1, every three cycles in the first 6 months and every 3 months thereafter. Safety evaluations were examined in every cycle by investigators. Adverse event (AE) data were collected up to 30 days after treatment discontinuation, immune-related AE (irAE) data were collected up to 90 days after the last dose of camrelizumab, and severity was graded using the National Cancer Institute-Common Terminology Criteria for Adverse Events v5.0.The immunohistochemical analysis of programmed cell death ligand-1 (PD-L1; antibody: CST13684)Whole-exome sequencing (Illumina sequencing platform) was performed to calculate the tumor mutational burden (TMB) score, defined as the number of somatic nonsynonymous mutations per megabase.